ROSELLINI SCIENTIFIC, LLC — Department of Health and Human Services SBIR Phase I: NHLBI

ROSELLINI SCIENTIFIC, LLC — SBIR Phase I award from Department of Health and Human Services.

Amount
$149,187
Agency
Department of Health and Human Services · National Institutes of Health
Program / Phase
SBIR · Phase I
Topic
NHLBI
Solicitation
PA15-269
NAICS
Place of performance
KY
Period
2017-02-01 → 2018-01-31

Description

Project Summary The Specific Aim of this proposal is to test the feasibility of using vagus nerve stimulation VNS for treating asthma related airway constriction that is refractory to current treatments There are approximately million people with asthma in the US About percent of these asthma sufferers experience early and late phase severe asthmatic bronchoconstriction that is refractory to current medication These patients account for more than half of health related asthma costs and the majority of its mortality This patient population accounts for emergency department visits per day hospitalizations per day and more than deaths annually There is currently no treatment for people who suffer from uncontrolled asthma Other percutaneous devices have proven effective for blocking the early phase of asthma attacks that are refractory to current therapy in an ED setting but there is currently no effective VNS device for outside of the ED setting In addition the efficacy of their device for blocking the later phase of the asthma response is unknown The late phase occurs in of individuals and may account for extended stand and returns to the ED Our goal is to provide patients with VNS for on demand treatment of both the early and late asthma responses in order to drastically improve quality of life prevent death and to obviate the need for visiting the ED However before evaluating our method in humans we must first determine if VNS is effective for halting both the early and the late phase of asthma In this Phase I study we will achieve our Specific Aim by evaluating the efficacy of VNS for blocking both early and late asthma responses in an ovalbumin OVA sensitized guinea pig model of asthma Guinea pigs are anesthetized with urethane g kg i p Heart rate and blood pressure are measured via a carotid artery cannula Both jugular veins are also cannulated for administration of drugs The left vagus nerve will be isolated and immersed in a pool of mineral oil and bipolar cuff electrode will be placed around the left cervical vagus Animalandapos s body temperature will be maintained at C using a heating blanket Animals are paralyzed with succinylcholine ml kg min i v and ventilated tidal volume ml g body weight at breaths per minute via a tracheal cannula using a constant volume pump Harvard Apparatus Co South Natick MA Bronchoconstriction measured as an increase in pulmonary inflation pressure Ppi via a pressure transducer on a sidearm of the tracheal cannula will be measured at stated time intervals after ovalbumin inhalation Test of Feasibility We must observe mean reduction of max respiratory system resistance when OVA is combined with VNS in comparison to sham VNS This value was chosen because it is both directly related to previously demonstrated pulmonary pressure change in guinea pigs and predictive of later clinically meaningful responses in humans Project Narrative This is a proposal to develop an on demand treatment for both immediate and long lasting symptoms of asthma using vagus nerve stimulation There are million Americans with asthma and approximately do not respond to current methods of treatment The proposed therapy seeks to mitigate debilitating symptoms and restore quality of life to patients suffering from uncontrolled asthma